“Powell Gilbert LLP is ahead simply
because every single person there is excellent.”

Legal 500

Bethan Hopewell, Partner, is a litigator with a strong technical background and advises clients in contentions IP matters, often with an international element, spanning a range of technologies and industry sectors



Bethan advises on a range of contentious IP matters, with a strong focus on multi-jurisdictional patent disputes. She works on matters spanning a wide range of technologies from electronics and telecoms to pharmaceuticals and biotechnology. This includes advising on issues arising from international technology standards, patent pools and associated licensing issues.


Owing to her strong scientific background, which includes a D. Phil in molecular biology, Bethan is adept at getting to grips with complex technical issues. Her background in biological sciences is of particular relevance to advising clients on complex patent matters, pharmaceutical regulatory issues and contested SPC disputes in the Life Sciences sector.


Bethan also provides freedom to operate and due diligence advice. In the contentious soft IP field, she advises clients on disputes concerning counterfeiting, brand and advertising issues. She also has experience in dealing with technology contract disputes.


Bethan represents clients in litigation before the UK Patents Court, Court of Appeal and Supreme Court. She also represents clients in European Patent Office opposition and appeal proceedings. In the context of coordinating multi-jurisdictional patent matters, Bethan also has considerable experience of actively assisting with litigation in various Scandinavian and European courts.


Bethan joined Powell Gilbert as an associate when it was founded in March 2007 and became a partner in 2016.


Bethan is a member of AIPPI and LSLA. In 2015 Bethan was shortlisted for the Euromoney LMG Woman in Business Law Rising Star Award.


Cases include
  • Illumina v Premaitha (non-invasive pre-natal testing)
  • Unwired Planet v Huawei (telecommunications)
  • Actavis v Warner-Lambert (pharmaceutical/ second medical use)
  • Wobben Properties v Siemens & others (wind turbines)
  • Rovi v Virgin Media & TiVo (electronics)
  • Eugen Seitz v KHS Corpoplast & Norgren (PET bottle manufacture)
  • HTC v Gemalto (telecommunications)
  • Eli Lilly v Human Genome Sciences (SPCs)
  • Human Genome Sciences v Eli Lilly (neutrokine alpha)
  • Sandoz v Napp (pharmaceutical)
  • ratiopharm v Napp (pharmaceutical)
  • Napp v Sandoz (pharmaceutical)
  • Dr Reddy’s v Eli Lilly (pharmaceutical)
  • Monsanto v Cargill (GM crops)
  • Ferag AG v Muller Martini Ltd (print trimming machinery)
  • Roche v Chiron (biotechnology)